Trade Report: Today, Agios Pharmaceuticals Inc. (AGIO) Receives New Coverage from Analysts at Oppenheimer Holdings Inc.

Today, Agios Pharmaceuticals Inc. (AGIO) Receives New Coverage from Analysts at Oppenheimer Holdings Inc.

Investment analysts at Oppenheimer Holdings Inc. started coverage on shares of Agios Pharmaceuticals Inc. (NASDAQ:AGIO) in a note issued to investors on Tuesday. The brokerage set a “market perform” rating on the biopharmaceutical company’s stock.

Several other equities analysts have also commented on the company. Cann assumed coverage on Agios Pharmaceuticals in a research note on Monday. They set a “market perform” rating on the stock. Credit Suisse Group AG reiterated a “buy” rating on shares of Agios Pharmaceuticals in a research note on Monday, November 21st. Leerink Swann reiterated a “market perform” rating on shares of Agios Pharmaceuticals in a research note on Friday, November 4th. Cowen and Company reiterated a “buy” rating on shares of Agios Pharmaceuticals in a research note on Thursday, November 3rd. Finally, Needham & Company LLC began coverage on Agios Pharmaceuticals in a research note on Monday, October 24th. They issued a “buy” rating and a $60.00 target price on the stock. Seven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Agios Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $61.94.

Agios Pharmaceuticals (NASDAQ:AGIO) traded up 1.63% during midday trading on Tuesday, hitting $61.89. 146,532 shares of the stock traded hands. The stock’s market cap is $2.60 billion. The company has a 50-day moving average of $54.70 and a 200-day moving average of $48.50. Agios Pharmaceuticals has a 12 month low of $33.50 and a 12 month high of $67.98.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($1.63) EPS for the quarter, missing the consensus estimate of ($1.52) by $0.11. The firm had revenue of $8.98 million for the quarter, compared to analysts’ expectations of $7.82 million. Agios Pharmaceuticals had a negative net margin of 341.56% and a negative return on equity of 53.39%. The business’s quarterly revenue was up 63.9% on a year-over-year basis. During the same quarter in the prior year, the business posted ($1.07) EPS. On average, equities research analysts anticipate that Agios Pharmaceuticals will post ($5.15) earnings per share for the current year.

In related news, Director Lewis Clayton Jr. Cantley sold 2,504 shares of Agios Pharmaceuticals stock in a transaction that occurred on Thursday, October 27th. The stock was sold at an average price of $48.94, for a total transaction of $122,545.76. Following the completion of the transaction, the director now directly owns 108,405 shares in the company, valued at $5,305,340.70. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Scott Biller sold 5,000 shares of Agios Pharmaceuticals stock in a transaction that occurred on Wednesday, October 5th. The shares were sold at an average price of $55.00, for a total value of $275,000.00. Following the transaction, the insider now owns 48,270 shares of the company’s stock, valued at $2,654,850. The disclosure for this sale can be found here. Corporate insiders own 10.55% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in AGIO. Redmile Group LLC bought a new position in shares of Agios Pharmaceuticals during the third quarter valued at $38,976,000. Price T Rowe Associates Inc. MD boosted its position in shares of Agios Pharmaceuticals by 49.0% in the third quarter. Price T Rowe Associates Inc. MD now owns 1,239,924 shares of the biopharmaceutical company’s stock valued at $65,493,000 after buying an additional 407,975 shares in the last quarter. Columbus Circle Investors bought a new position in shares of Agios Pharmaceuticals during the third quarter valued at $15,999,000. BB Biotech AG boosted its position in shares of Agios Pharmaceuticals by 12.1% in the third quarter. BB Biotech AG now owns 2,649,528 shares of the biopharmaceutical company’s stock valued at $139,948,000 after buying an additional 286,207 shares in the last quarter. Finally, Capital Guardian Trust Co. boosted its position in shares of Agios Pharmaceuticals by 57.6% in the second quarter. Capital Guardian Trust Co. now owns 668,100 shares of the biopharmaceutical company’s stock valued at $27,990,000 after buying an additional 244,178 shares in the last quarter. Institutional investors own 89.27% of the company’s stock.

About Agios Pharmaceuticals

Related posts

Leave a Comment